Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran

[1]  Amy M. Sitapati,et al.  NCCN Guidelines Insights: Breast Cancer, Version 1.2017. , 2017, The Journal of the National Comprehensive Cancer Network.

[2]  T. Miyoshi,et al.  A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting , 2017, Supportive Care in Cancer.

[3]  Zhou Wang,et al.  A cost-utility analysis of risk model-guided versus physician’s choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach , 2017, Supportive Care in Cancer.

[4]  T. Higashi,et al.  Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk , 2017, JAMA oncology.

[5]  B. Rapoport.  Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management , 2017, Front. Pharmacol..

[6]  R. Gralla,et al.  Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists , 2017, Supportive Care in Cancer.

[7]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology Focused Guideline Update. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Aapro,et al.  Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. , 2016, The New England journal of medicine.

[9]  Aubrey Waddell,et al.  Compliance with National Comprehensive Cancer Network anti-emesis guidelines in a Community Hospital Cancer Center , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[10]  F. Caracuel,et al.  Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[11]  M. Zaidan,et al.  Assessing prescribing patterns for the prevention of chemotherapy-induced nausea and vomiting in the national center for cancer care and research , 2015, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[12]  M. Hockenberry,et al.  Improving Adherence to Evidence-Based Guidelines for Chemotherapy-Induced Nausea and Vomiting , 2015, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

[13]  H. Sachin,et al.  Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens , 2015 .

[14]  S. Hingmire,et al.  Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens , 2015, South Asian Journal of Cancer.

[15]  A. Molassiotis,et al.  Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. , 2014, Journal of pain and symptom management.

[16]  A. Molassiotis,et al.  International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. , 2014, European journal of pharmacology.

[17]  Stephen Szabo,et al.  Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. , 2014, Journal of oncology practice.

[18]  A. Molassiotis,et al.  Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting , 2013, Supportive Care in Cancer.

[19]  I. Narita,et al.  The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy , 2013, Supportive Care in Cancer.

[20]  A. Molassiotis,et al.  The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  W. Yeo,et al.  Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients. , 2011, Breast cancer.

[22]  E. Bayliss,et al.  Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study , 2011, Supportive Care in Cancer.

[23]  S. Brearley,et al.  Use of antiemetics in the management of chemotherapy-related nausea and vomiting in current UK practice , 2011, Supportive Care in Cancer.

[24]  J. Nortier,et al.  Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics , 2011, International Journal of Clinical Pharmacy.

[25]  N. Aaronson,et al.  Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study , 2011, Supportive Care in Cancer.

[26]  H. Schmoll,et al.  Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. , 2007, The oncologist.

[27]  R. Kaiser.  Antiemetic guidelines: are they being used? , 2005, The Lancet. Oncology.

[28]  G. Dranitsaris,et al.  Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study , 2001, Supportive Care in Cancer.